No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Qingdao Vland Biotech Inc. specializes in the research, development, and production of enzymes, probiotics, animal vaccines, and veterinary health products. Its extensive product range features enzymes for animal feed, industrial uses, and food processing, along with various probiotics, such as aquaculture premixes, general health supplements, and both animal and plant-specific formulations. The company also provides a comprehensive array of animal vaccines and biological solutions, including both live and inactivated vaccines for poultry and swine, in addition to antibodies. Its offerings extend to poultry pharmaceuticals, covering antiparasitic, antiviral, and nutritional medications, alongside disinfectants. Furthermore, it supplies traditional Chinese veterinary remedies designed for aquatic species, poultry, and livestock, including laying hens. Vland Biotech's diverse clientele operates across numerous sectors, such as agriculture, animal husbandry, textile manufacturing, papermaking, household cleaning and detergents, food production, biofuel development, and environmental protection. This entity, established in 2005 and headquartered in Qingdao, China, operates as a subsidiary of Qingdao Kangdien Industrial Co., Ltd.

• Larimar Therapeutics, Inc.
• Medtide Inc.
• Avacta Group Plc
• Qyuns Therapeutics Co., Ltd.
• EirGenix Inc.
• BioAge Labs Inc.
• Shanghai ZJ Bio-Tech Co., Ltd.
• Ocugen, Inc.